hale & tempest global generics marketplace dr. brian w tempest [email protected] uk...
TRANSCRIPT
![Page 1: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/1.jpg)
Hale & Tempest
Global Generics Marketplace
Dr. Brian W Tempest
www.briantempest.com
UK
18,19,20 March 2014
![Page 2: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/2.jpg)
Hale & Tempest
![Page 3: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/3.jpg)
Hale & Tempest
1. Global Healthcare
2. Big Pharma
3.Global Generic Marketplace
4.Global Generic Companies
5.Indian Generic Marketplace
6.Indian Generic Companies
7. Country Generic Markets
8. Biosimilars
9. Generic Distribution
10. Over The Counter Consumer Medines
11. Contract Manufacturers
![Page 4: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/4.jpg)
Hale & Tempest
Global Healthcare & Big Pharma
Chesapeake
Dr. Brian W Tempest
www.briantempest.com
UK
March 2014
![Page 5: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/5.jpg)
Hale & Tempest
1. Global Healthcare
![Page 6: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/6.jpg)
Hale & Tempest
There are only a few certain thingsSource: T Stevenson, Fidelity Worldwide Investment Director, S Telegraph April 21 2013
•Populations growth
•Ageing
•Expansion of the World’s Middle Classes
•Increasing demand for healthcare is as close to given as investors can hope for
![Page 7: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/7.jpg)
Hale & Tempest
Rise of the Middle Classes source: Frost & Sullivan
![Page 8: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/8.jpg)
Hale & Tempest
Aging in OECDsource: EGA
![Page 9: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/9.jpg)
Hale & Tempest
Global Healthcare Growth by Region Source: Sunday Telegraph April 21 2013
![Page 10: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/10.jpg)
Hale & Tempest
Healthcare costs versus GDP & Wages
![Page 11: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/11.jpg)
Hale & Tempest
Public Health as % of GDPSource: UNDP 15 October 2012
Cuba 9.7% USA 9.5% France 9.3% UK 8.1%
Brazil 4.2% RSA 3.9% Russia 3.2% China 2.7% India 1.2%
![Page 12: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/12.jpg)
Hale & Tempest
Military vs Healthsource: FT 24February 2014
![Page 13: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/13.jpg)
Hale & Tempest
Public Health Reform Everywhere
![Page 14: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/14.jpg)
Hale & Tempest
OECD Healthcare Expenditure Growth
source: Annalisa Belloni OECD at EGA Conference 13 June 2013
![Page 15: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/15.jpg)
Hale & Tempest
Everybody Concerned about Health Costs
![Page 16: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/16.jpg)
Hale & Tempest
Healthcare as % of Government Spend
source: WHO, Jefferies
![Page 17: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/17.jpg)
Hale & Tempest
Public & Private Healthcare as % of GDP
source: WHO, India is <4%
![Page 18: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/18.jpg)
Hale & Tempest
How Easy to Start a Business in EMs
source: Mint 13 October 2013
![Page 19: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/19.jpg)
Hale & Tempest
Number of Companies with Active R&D Pipelines source: Citeline Pharma R&D Annual Review 2013
![Page 20: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/20.jpg)
Hale & Tempest
Worldwide R&D Spend
source: Evaluate Pharma 23 June 2013
![Page 21: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/21.jpg)
Hale & Tempest
R&D Spending by Countrysource: Economist March 22 2014
![Page 22: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/22.jpg)
Hale & Tempest
Rise of Asia R&Dsource: Economist March 22 2014
![Page 23: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/23.jpg)
Hale & Tempest
Emerging Markets Pharma Markets, $b
Source: Citi Research August 2013
![Page 24: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/24.jpg)
Hale & Tempest
Value of EM Bourses - limited availabilitysource: January 18 2014 Economist
![Page 25: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/25.jpg)
Hale & Tempest
OECD vs. BRICS
source: FT 9 October 2013
![Page 26: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/26.jpg)
Hale & Tempest
Emerging Marketssource: Business India December 8 2013
![Page 27: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/27.jpg)
Hale & Tempest
The Need for Universal Healthcare
source: ET 2 Aug 2013
![Page 28: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/28.jpg)
Hale & Tempest
Healthcare will explode further in Asia
![Page 29: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/29.jpg)
Hale & Tempest
Asian Healthcare Expenditure $b
source: EIU for countries PRC, HK, I, Ind, M, P, Si, SK, Tw , Th, V
![Page 30: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/30.jpg)
Hale & Tempest
Pharmaceutical Imports into USA source: Chemistry World July 2012
![Page 31: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/31.jpg)
Hale & Tempest
Cipla - Washington Post Ad
![Page 32: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/32.jpg)
Hale & Tempest
Sovaldi (sofosbuvir) for Hepatitis CSource: Pharmatimes February 7 2014
•In USA Gilead Sciences charges Sovaldi at $1000 a day for a 12 week course -$84,000
•The cost of manufacture of the same 12 week course is $68 to $136 according to MSF generating a gross profit over 99%
•In India and other emerging markets Gilead plans to charge $2,000 for a 24 week course leading to a gross profit of 86%
![Page 33: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/33.jpg)
Hale & Tempest
Evolving Emerging Markets IP PolicySource: Leaky Pharma 27 Jan 2014
•“This is genocide, This can sentence South Africans to death” – RSA Health Minister (Motsoaldi)
•1998 Big Pharma, Merck vs Mandela, PR disaster
•Enhanced Therapeutic Efficacy vs Incremental Efficacy
•2014 Merck, PhRMA, Lobbyist PAE vs RSA IP policy
•OECD growth +1-4% vs Emerging Markets at +10-13%
•WHO Executive Board – “we cannot be sidetracked from our course of action of defending public health and the right to life” (DG Precious Matsoso)
![Page 34: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/34.jpg)
Hale & Tempest
Davos 2014 -Ten Global Risks of Highest Concern source: Davos 2014
![Page 35: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/35.jpg)
Hale & Tempest
Aid by Countrysource: Economist 12 April 2014
![Page 36: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/36.jpg)
Hale & Tempest
2. Big Pharma
![Page 37: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/37.jpg)
Hale & Tempest
Big Pharma Business Model Broken source: Pharmatimes World News April 2012
![Page 38: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/38.jpg)
Hale & Tempest
Pharma in Crisis Source: Pharmatimes February 2013
![Page 39: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/39.jpg)
Hale & Tempest
A Slide from a UK Headhunter
![Page 40: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/40.jpg)
Hale & Tempest
Top 10 Marketing Settlements Source: Fiercepharma 26 June 2012
GSK $3b 2012 Pfizer $2.3b 2009 J&J $2.2b 2012 Abbott 1.6b 2012 Lilly $1.4b 2009 Merck $1.0b 2011 Serono $0.7b 2005 Perdue $0.7b 2007 Allergan $0.6b 2010
![Page 41: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/41.jpg)
Hale & Tempest
A Pfizer Decade of Bribery source: FT August 7 2012
![Page 42: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/42.jpg)
Hale & Tempest
The Biggest Healthcare Fraud in HistorySource: Daily Mail 3 July 2012
![Page 43: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/43.jpg)
Hale & Tempest
China Bribery Investigations
source: Jefferies November 2013
![Page 44: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/44.jpg)
Hale & Tempest
Emerging Markets are Not so Easy
![Page 45: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/45.jpg)
Hale & Tempest
Will Big Pharma Change?
![Page 46: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/46.jpg)
Hale & Tempest
Or be like Popeye the sailor man
“I Yam what I Yam what I Yam”
![Page 47: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/47.jpg)
Hale & Tempest
The Strategic Changes by Big PharmaSource: FT December 5 2012, Franz Humer, Roche Chairman
•Possible to cut 30-50% off development costs via CT efficiencies
•Shift from product focus to patient focus using diagnostic tools
• In Europe there isn’t one Government or politician interested in the health of the Industry
•USA & Latin American countries open to rewarding innovation
•Industry has to change fundamentally how it manages costs
•Leaner headquarters & smaller central functions •Division of the industry into 2 parts
• A Innovative businesses able to charge a premium price
• B Large scale manufacturers who can compete on cost
![Page 48: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/48.jpg)
Hale & Tempest
Divestment & Spin Off StrategiesSource: IPA 2013
•Novartis - Blood Diagnostics, Animal Health, OTC, Vaccines•Bayer - Bayer Material Sciences likely
•Abbott - Abbvie (pharma assets)
•Pfizer - Nutrition, Zoetis Animal Health
•Merck - separate growth businesses from value businesses, Consumer OTC
•GSK - tail products to Aspen, drinks brands
•J&J - Diagnostics
![Page 49: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/49.jpg)
Hale & Tempest
2013 The Year of 8 Blockbusterssource: Evaluate March 2014
![Page 50: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/50.jpg)
Hale & Tempest
2013 the 8 Blockbusterssource: Evaluate March 2014
![Page 51: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/51.jpg)
Hale & Tempest
Big Pharma Top 10 by 2012 Sales
Source: FiercePharma 29 November 2013
![Page 52: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/52.jpg)
Hale & Tempest
Top 10 Medtech Companies
source: Evaluate Pharma, 23 September 2013
![Page 53: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/53.jpg)
Hale & Tempest
Pharma & Medtech Global Markets
source: Evaluate 23 September 2013
![Page 54: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/54.jpg)
Hale & Tempest
Global Pharma Salessource: Evaluate April 2014
![Page 55: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/55.jpg)
Hale & Tempest
Sales at Risksource: Evaluate April 2014
![Page 56: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/56.jpg)
Hale & Tempest
Global Pharma sales lost & sales gainedsource: Evaluate March 2014
![Page 57: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/57.jpg)
Hale & Tempest
Biggest Expected Launches of 2014source: EvaluatePharma
![Page 58: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/58.jpg)
Hale & Tempest
Strength of Local Companiessource: IMS May 2012
![Page 59: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/59.jpg)
Hale & Tempest
Big Pharma Top Risers & Fallers in 2013source: Evaluate March 2014
![Page 60: Hale & Tempest Global Generics Marketplace Dr. Brian W Tempest brian.tempest@clara.co.uk UK 18,19,20 March 2014](https://reader035.vdocuments.us/reader035/viewer/2022062804/56649d045503460f949d7c1c/html5/thumbnails/60.jpg)
Hale & Tempest
2013 a healthy year for Pharmasource: Evaluate March 2014